Singulex Inc, Alameda, Calif, has entered into a strategic collaboration with Qiagen, Hilden, Germany, focused on the development of companion diagnostics. Through the collaboration, Qiagen will have access to Singulex’s single molecule counting (SMC) immunodiagnostics platform, adding immunoassay capabilities to Qiagen’s existing molecular testing services for the development of companion diagnostics. Additionally, Qiagen will have access to Singulex’s CLIA-licensed laboratory.

Singulex will provide Qiagen with access to its proprietary SMC immunodiagnostics platform, and the companies intend to collaborate on a range of disease applications.

Guido Baechler,

Guido Baechler, Singulex.

“As the next-generation immunodiagnostics company, this strategic partnership is another proof point for the versatility of Singulex’s high-sensitivity SMC technology,” says Guido Baechler, president and CEO of Singulex. “We are pleased to collaborate with Qiagen and look forward to our work together.”

Singulex believes the collaboration with Qiagen will expand access to and utilization of its proprietary SMC platform, and is an important validation of high-sensitivity immunoassays and its versatility of applications. SMC is currently available via Singulex’s CLIA-licensed laboratory, with future application through the SGX Clarity system, a fully automated in vitro diagnostic platform currently in development and not yet approved for sale.

For more information, visit Qiagen or Singulex.